Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

This trial is testing a combination of savolitinib (a drug that blocks a protein called MET, which drives cancer growth) plus docetaxel (a standard chemotherapy) as a second-line treatment for people with advanced non-small cell lung cancer (NSCLC) that overexpresses MET but does not have the common driver mutations (EGFR, ALK, ROS1, or MET exon 14). **You may be eligible if...** - You are 18 or older with confirmed locally advanced or metastatic NSCLC - Your tumor does not have EGFR, ALK, ROS1 mutations, or MET exon 14 skipping mutations - Your tumor overexpresses MET (as confirmed by testing) - You have already received one prior first-line systemic treatment for advanced NSCLC - You have adequate organ function and performance status **You may NOT be eligible if...** - You have had more than one prior treatment for advanced disease - You have already received a MET inhibitor - You have active brain metastases or serious infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.